Academic Journal
[LSD revisited: Mechanisms of action and therapeutic potential in mental health].
| Τίτλος: | [LSD revisited: Mechanisms of action and therapeutic potential in mental health]. |
|---|---|
| Μεταγλωττισμένος Τίτλος: | Le LSD revisité : mécanismes d’action et potentiel en santé mentale. |
| Συγγραφείς: | Bouloufa A; Institut cellule souche et cerveau, Inserm U1208, université Claude-Bernard Lyon 1, 18, avenue Doyen-Lépine, 69500 Bron, France., Delcourte S; Institut cellule souche et cerveau, Inserm U1208, université Claude-Bernard Lyon 1, 18, avenue Doyen-Lépine, 69500 Bron, France., Delannay T; Institut cellule souche et cerveau, Inserm U1208, université Claude-Bernard Lyon 1, 18, avenue Doyen-Lépine, 69500 Bron, France., Haddjeri N; Institut cellule souche et cerveau, Inserm U1208, université Claude-Bernard Lyon 1, 18, avenue Doyen-Lépine, 69500 Bron, France. Electronic address: nasser.haddjeri@inserm.fr. |
| Πηγή: | L'Encephale [Encephale] 2026 Oct; Vol. 52 (5), pp. 519-528. Date of Electronic Publication: 2026 Apr 09. |
| Τύπος έκδοσης: | Journal Article; Review; English Abstract |
| Γλώσσα: | French |
| Στοιχεία περιοδικού: | Publisher: Masson Country of Publication: France NLM ID: 7505643 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 0013-7006 (Print) Linking ISSN: 00137006 NLM ISO Abbreviation: Encephale Subsets: MEDLINE |
| Imprint Name(s): | Publication: Paris Masson Original Publication: 1906-1996: Paris : Delarue |
| Ιατρικοί όροι (MeSH): | Lysergic Acid Diethylamide*/therapeutic use , Lysergic Acid Diethylamide*/pharmacology , Lysergic Acid Diethylamide*/adverse effects , Major Depressive Disorder*/drug therapy , Major Depressive Disorder*/psychology , Hallucinogens*/therapeutic use , Hallucinogens*/pharmacology, Antidepressive Agents/therapeutic use ; Antidepressive Agents/pharmacology ; Depressive Disorder, Treatment-Resistant/drug therapy ; Depressive Disorder, Treatment-Resistant/psychology ; Humans |
| Περίληψη: | Major depressive disorder (MDD) represents a colossal worldwide burden of health, affecting more than 350 million individuals. While traditional antidepressants with mechanisms of action at the serotonin, dopamine, or norepinephrine pathways are routinely prescribed, approximately one-third of patients fail to achieve adequate remission and develop treatment-resistant depression (TRD). This therapeutic shortfall underscores the necessity for novel approaches to treatment. Over the past two decades there has been a resurgence of scientific interest in psychedelics, such as lysergic acid diethylamide (LSD). LSD's primary pharmacological effect is modulation of the 5-HT2A serotonin receptor and the glutamatergic system, both of which have been involved in neuroplasticity. It has been hypothesized that it is these neurobiological effects that are likely to be behind the rapid and sustained antidepressant responses observed in the early clinical studies. Clinical trials are currently underway to determine the safety and efficacy of LSD for the treatment of MDD. However, psychedelic research is not without methodological hurdles, such as providing meaningful placebos to account for LSD's idiosyncratic subjective effects. Also, physicians need specialized training to help navigate these deeply psychologically immersive states experienced in the context of psychedelic-assisted therapy. While LSD-assisted therapy remains experimental, its therapeutic potential is increasingly recognized, especially given the limitations of available treatments for TRD. Continued rigorous research is necessary to achieve careful integration of psychedelic therapies into standard clinical practice. (Copyright © 2026 L'Encéphale, Paris. Published by Elsevier Masson SAS. All rights reserved.) |
| Contributed Indexing: | Keywords: Antidépresseurs à action rapide; Dépression résistante au traitement; Fast-acting antidepressants; LSD; Psychedelics; Psychédéliques; Treatment-resistant depression |
| Substance Nomenclature: | 8NA5SWF92O (Lysergic Acid Diethylamide) 0 (Hallucinogens) 0 (Antidepressive Agents) |
| Entry Date(s): | Date Created: 20260410 Date Completed: 20260912 Latest Revision: 20260912 |
| Update Code: | 20260913 |
| DOI: | 10.1016/j.encep.2026.02.008 |
| PMID: | 41963179 |
| Βάση Δεδομένων: | MEDLINE |
| ISSN: | 0013-7006 |
|---|---|
| DOI: | 10.1016/j.encep.2026.02.008 |